Would you like to join this study on acne?

ACNE-ID is looking for more sites to recruit young people with acne

The study is investigating a reduced daily dose of oral isotretinoin treatment for acne

It will look at the benefits and harms of two different doses of isotretinoin for the treatment of severe acne in young adults, but they need more sites to recruit more people to the study.

The detail: Acne-ID is a 2-arm, parallel-group, individually randomised, multicentre, non-inferiority trial with an internal pilot phase.   They aim to recruit 800 people with acne aged 12 to 24 years. Each participant will be followed up for 12months. We will compare a low-dose isotretinoin strategy (the intervention) with standard care dosing (the comparator). 

1. Low-dose isotretinoin (0.2-0.3 mg/kg/day)
2. Standard-dose isotretinoin (>0.5mg/kg/day) 

Eligibility: People with severe acne aged between 12 to 24 where the decision to start on isotretinoin has already been made with their clinician (before they come into the trial).

Primary outcome: Acne clearance, defined by the Comprehensive Acne Severity Score, at the end of treatment course.  Secondary outcomes are - Side effects and tolerability, Change in mood, Quality of life, Treatment satisfaction, Recurrence of acne, Costs to patients and the NHS.

There are two nested sub-studies, a health economic evaluation and a qualitative study to develop a clinical decision support tool. 

Interested sites can email the study team: acne-id@nottingham.ac.uk   You will need to complete a site selection questionnaire (SSQ) ACNE-ID SITE SELECTION QUESTIONNAIRE [app.onlinesurveys.jisc.ac.uk] and have a short meeting with the study team (30-60 mins), with usually the Principal Investigator and someone from the research team.

For more information see the study website: https://www.acne-id.ac.uk/